Atlas Venture Associates Opportunity I, L.P.'s Net Worth
Estimate Recalculated Jun 18, 2025 08:57PM EST
Who is Atlas Venture Associates Opportunity I, L.P.
Atlas Venture Associates Opportunity I, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., Third Harmonic Bio, Inc., and Homology Medicines, Inc..
SEC CIK
Atlas Venture Associates Opportunity I, L.P.'s CIK is 0001780065
Past Insider Trading and Trends
No data available
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
